|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal
executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
||
|
|
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibits.
|
Press Release of Rocket Pharmaceuticals, Inc. dated March 26, 2024.
|
Rocket Pharmaceuticals, Inc.
|
||
Date: March 29, 2024
|
By:
|
/s/ Martin Wilson
|
Martin Wilson
|
||
General Counsel and Chief Corporate Officer, SVP
|
|
•
|
Kinnari Patel, Pharm.D., MBA, has been appointed President, Head of
R&D and Chief Operating Officer. Dr. Patel will be focused on R&D with oversight spanning research through late-stage development and manufacturing. In addition, she will continue in her capacity as COO, driving company operations
aimed toward advancing the company’s key strategic priorities.
|
•
|
Jonathan Schwartz, M.D., has been appointed Chief Medical & Gene
Therapy Officer, with his remit spanning Research and Discovery as well as Clinical Development. Dr. Schwartz will bring deep and seasoned scientific and clinical thought leadership instrumental in continuing to develop and advance Rocket’s
current and future pipeline.
|
•
|
Mark White, MB.ChB, has been appointed General Manager, Commercial
Affairs, leading the Medical Affairs, Marketing, Commercial Operations, and Value & Access functions. Dr. White’s extensive drug development and franchise leadership experience, combined with the benefit of bringing these functions
together under his leadership, best positions Rocket for long-term success with highly complex therapies aimed at rare diseases.
|
•
|
Martin Wilson. J.D., has been appointed General Counsel & Chief
Corporate Officer, and will lead Legal, Compliance, and Corporate Development. This evolution creates a newly integrated team aimed at advancing Rocket’s corporate strategy, led by Mr. Wilson’s strong legal and strategic acumen and
experience.
|
Document and Entity Information |
Mar. 25, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 25, 2024 |
Entity File Number | 001-36829 |
Entity Registrant Name | Rocket Pharmaceuticals, Inc. |
Entity Central Index Key | 0001281895 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 04-3475813 |
Entity Address, Address Line One | 9 Cedarbrook Drive |
Entity Address, City or Town | Cranbury |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 08512 |
City Area Code | 646 |
Local Phone Number | 440-9100 |
Title of 12(b) Security | Common stock, $0.01 par value |
Trading Symbol | RCKT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
K5\7U5M
M95FDVNBQPB[DS;8MC &NM#$ZD;\-C;F+NI>N*"-D@!;'ZC:FMS5Q\[DL=OOJ
M\C95PE!=,5>98(E'#@Q1[# 5@$?P:A.6%Q#$V5['N\4E\ -B[NIK^+XV5BN"$0_*W?
M(1: 5G,(L19Y6( S,;1BC+B)\'\C@]2H4)G
MKB?4-+L\DZV)Y?1$=M.G]GEL53HK_R!RCR;!#_,?D1#L^8EL746(.8LR@JIJ
M\RQV6T$]('A)[FC(WU=W^[R3CN&-?2B.C^=F5P6G^!Q5F**I_EXX-AYRW#.KI92INUE?0]0:6:2T